CC
APGE icon

Commodore Capital’s Apogee Therapeutics APGE Stock Holding History

Commodore Capital’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-290,000
Closed -$11.5M – 35
2025
Q3 		$11.5M Hold
290,000
– – 0.56% 29
2025
Q2 		$12.6M Hold
290,000
– – 0.89% 26
2025
Q1 		$10.8M Hold
290,000
– – 0.8% 25
2024
Q4 		$13.1M Hold
290,000
– – 0.96% 23
2024
Q3 		$17M Hold
290,000
– – 1.06% 28
2024
Q2 		$11.4M Hold
290,000
– – 0.78% 27
2024
Q1 		$19.3M Buy
290,000
+40,000
+16% +$1.75M 1.29% 26
2023
Q4 		$6.99M Hold
250,000
– – 0.61% 30
2023
Q3 		$5.33M Buy
+250,000
New +$5.51M 0.62% 27

Other funds holding APGE

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Commodore Capital's APGE Position: Q4 2025 in Review

Commodore Capital sold out of Apogee Therapeutics (APGE) in Q4 2025, closing a stake of 290,000 shares — an estimated $11.5M sold.

Commodore Capital first reported a position in APGE in Q3 2023 and held it in 9 quarters. The position peaked at $19.3M in Q1 2024. 206 funds tracked by Wall St. Rank hold APGE as of Q4 2025.

  • Commodore Capital reported no remaining Apogee Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Commodore Capital sold 290,000 Apogee Therapeutics shares in Q4 2025, an estimated $11.5M.
  • Commodore Capital first reported a position in Apogee Therapeutics in Q3 2023 and held it in 9 quarters.
  • Commodore Capital's Apogee Therapeutics position peaked at $19.3M in Q1 2024.
  • 206 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q4 2025.

Based on Commodore Capital's 13F filing for Q4 2025, filed 17 Feb 2026.